Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

curium pharma uk ltd - gallium [ga-67] citrate - solution for injection - 37mbq/1ml

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

gallium(67ga) citrate -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

lantheus mi australia pty ltd - gallium(67ga) citrate -

Spojené státy - angličtina - NLM (National Library of Medicine)

ucsf radiopharmaceutical facility - gallium ga-68 gozetotide (unii: zj0ekr6m10) (gallium ga-68 gozetotide - unii:zj0ekr6m10) - gallium ga 68 gozeotide injection is indicated for positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer: - with suspected metastasis who are candidates for initial definitive therapy. - with suspected recurrence based on elevated serum prostate-specific antigen (psa) level. none risk summary gallium ga 68 gozetotide injection is not indicated for use in females. there are no available data with gallium ga 68 gozetotide injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. all radiopharmaceuticals, including gallium ga 68 gozetotide injection, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. animal reproduction studies have not been conducted with gallium ga 68 gozetotide injection. risk summary gallium ga 68 gozetotide injection is not indicated for use in females. there ar

Spojené státy - angličtina - NLM (National Library of Medicine)

genta incorporated - gallium nitrate (unii: vra0c6810n) (gallium cation - unii:f7k5mp217w) - gallium nitrate 25 mg in 1 ml - ganite is indicated for the treatment of clearly symptomatic cancer-related hypercalcemia that has not responded to adequate hydration. in general, patients with a serum calcium (corrected for albumin) < 12 mg/dl would not be expected to be symptomatic. mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without diuretics). in the treatment of cancer-related hypercalcemia, it is important first to establish adequate hydration, preferably with intravenous saline, in order to increase the renal excretion of calcium and correct dehydration caused by hypercalcemia. ganite should not be administered to patients with severe renal impairment (serum creatinine > 2.5 mg/dl).

Spojené státy - angličtina - NLM (National Library of Medicine)

ucla biomedical cyclotron - gallium ga-68 gozetotide (unii: zj0ekr6m10) (gallium ga-68 gozetotide - unii:zj0ekr6m10) - gallium ga 68 gozetotide injection is indicated for positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer: - with suspected metastasis who are candidates for initial definitive therapy. - with suspected recurrence based on elevated serum prostate-specific antigen (psa) level. none risk summary gallium ga 68 gozetotide injection is not indicated for use in females. there are no available data with gallium ga 68 gozetotide injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. all radiopharmaceuticals, including gallium ga 68 gozetotide injection, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. animal reproduction studies have not been conducted with gallium ga 68 gozetotide. risk summary gallium ga 68 gozetotide injection is not indicated for use in females. there are no data

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

ge healthcare limited - gallium (67 ga) citrate - solution for injection - 37 mbq/ml

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

cis bio international - gallium (67 ga) citrate - solution for injection

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

gallium(67ga) citrate -

Spojené státy - angličtina - NLM (National Library of Medicine)

uihc – p e t imaging center - edotreotide gallium ga-68 (unii: y68179sy2l) (edotreotide gallium ga-68 - unii:y68179sy2l) - ga 68 dotatoc injection is indicated for use with positron emission tomography (pet) for the localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult and pediatric patients. none risk summary there are no available data on the use of ga 68 dotatoc injection in pregnant women to identify a risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with ga 68 dotatoc. however, all radiopharmaceuticals, including ga 68 dotatoc injection have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. if considering ga 68 dotatoc injection administration to a pregnant woman, inform the patient of the potential for adverse pregnancy outcomes based on the radiation dose from ga 68 dotatoc injection and the gestational timing of exposure. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregn